Cerevel Therapeutics Holdings, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of cash flows

In millions of USD, except per-share amounts

	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash flows used in operating activities:
Depreciation and amortization
Non-cash rent expense under operating leases
Adjustments to operating lease expense
Equity-based compensation
Change in fair value of Equity Commitment
Change in fair value of Share Purchase Option
Change in fair value of Equity Commitment and Share Purchase Option
Change in fair value of financing liabilities (including related party amounts), (Notes 8, 11 and 20)
Change in fair value of private placement warrants
Write-off of deferred offering costs
Non-cash interest expense
Amortization of premiums and accretion of discounts on marketable securities
Other non-cash items

Changes in operating assets and liabilities, net:
Prepaid expenses and other current assets
Operating lease asset
Other assets
Accounts payable
Accrued expenses and other liabilities
Operating lease liability

Net cash flows used in operating activities
Cash flows from investing activities:
Purchases of marketable securities
Maturities and redemptions of marketable securities
Purchases of property and equipment
Net cash flows provided by (used in) investing activities
Cash flows from financing activities:
Proceeds from Business Combination Transaction, net of offering costs paid (see Note 3)
Deferred costs related to abandoned initial public offering and other financing activities
Proceeds from issuance of common stock related to follow-on offering, net of offering costs
Proceeds from the Business Combination Transaction, net of offering costs
Proceeds from the exercise of public warrants
Proceeds from the exercise of stock options and ESPP purchases
Proceeds from financing liability, related party
Proceeds from financing liability
Proceeds from issuance of 2027 convertible senior notes, net of offering costs
Deferred costs related to financing activities
Net cash flows provided by financing activities

Net increase in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash, beginning of the period
Cash, cash equivalents and restricted cash, end of the period
Fixed asset additions included in accounts payable and other current liabilities
Unpaid offering costs included in accounts payable and other current liabilities
Supplemental disclosure of cash flow information:
Cash paid for interest
Cash paid for income taxes
Supplemental cash flow disclosures from non-cash investing and financing activities:
Fixed asset additions included in accounts payable and other current liabilities
Offering costs included in accounts payable and other current liabilities
Operating lease assets obtained in exchange for operating lease liabilities
Cashless exercise of private placement warrants
Settlement of Equity Commitment liability upon issuance of Series A-1 Preferred Stock and Series A Common Stock
Reclassification of deferred financing costs to additional paid-in capital

Comments